Lexaria Bioscience Revenue Plunges 94% to $20,000 in H1 FY2026
The drug delivery technology company reported revenue of just $20,000 for the six months ending February 28, down from $357,923 in the year-ago period. Net loss narrowed to $3.0 million from $5.4 million.
Lexaria Bioscience Corp., a drug delivery technology company, reported revenue of $20,000 for the six months ending February 28, down 94% from $357,923 in the same period a year earlier. The company posted a net loss of $3.0 million for the period, compared to a loss of $5.4 million in the prior-year half. Read more earnings reports.
For the three months ending February 28, revenue totaled $20,000, down from $174,000 in the year-ago quarter. The quarterly net loss was $1.4 million, compared to a loss of $2.7 million in the prior-year quarter.
Operating Expenses Drop by Half
Operating expenses for the six-month period fell to $3.0 million from $5.8 million a year earlier. Research and development spending declined to $1.1 million from $3.6 million in the prior-year period.
The operating loss for the six months was $3.0 million, compared to a loss of $5.4 million in the year-ago period. Cash used in operations totaled $3.1 million, compared to $4.2 million in the prior-year half.
Balance Sheet Strengthens
Cash and restricted cash stood at $5.1 million as of February 28, up from $1.8 million at the end of August 2025. Total assets increased to $6.5 million from $4.2 million over the same period.
The company raised $6.5 million from financing activities during the six months. Total liabilities fell to $277,000 from $1.6 million, while stockholders' equity more than doubled to $6.6 million from $3.0 million.
Shares outstanding increased to 24.9 million as of February 28, up from 19.6 million at the end of August 2025. Diluted loss per share for the six months was $0.13, compared to $0.32 in the prior-year period.
Financial Summary
| Metric | Six Months Ending Feb 28, 2026 | Six Months Ending Feb 28, 2025 |
|---|---|---|
| Revenue | $20,000 | $357,923 |
| Operating Loss | ($3,025,534) | ($5,441,719) |
| Net Loss | ($3,044,986) | ($5,416,911) |
| R&D Expenses | $1,146,728 | $3,639,136 |
| Cash from Operations | ($3,147,970) | ($4,223,936) |
| Diluted EPS | ($0.13) | ($0.32) |
Accounts receivable dropped to $42,029 from $368,358 between August 31, 2025 and February 28, 2026. Property, plant and equipment edged up to $242,931 from $228,129 over the same period.